- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Adverum Biotechnologies
Adverum Biotechnologies, Inc. operates as a biotechnology company. The Company focuses on targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, and wet age-related macular degeneration.
Stock Analysis
last close
$1.47
1-mo return
-15.5%
3-mo return
61.8%
avg daily vol.
1.01M
52-week high
2.57
52-week low
0.8
market cap.
$145M
forward pe
-
annual div.
-
roe
-44.4%
ltg forecast
-
dividend yield
-
annual rev.
$--
inst own.
65.4%
